Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure

Journal of Cardiovascular Pharmacology

Volumn 41, Issue SUPPL. 1, 2003, Pages

  Watanabe, Kenichi ^a   Juan, Wen ^a   Narasimman, Gurusamy ^a   Ma, Meilei ^a   Inoue, Mikio ^a   Saito, Yuki ^a   Wahed II, Mir ^a   Nakazawa, Mikio ^b   Hasegawa, Go ^c   Naito, Makoto ^c   Tachikawa, Hitoshi ^c   Tanabe, Naohito ^c   Kodama, Makoto ^c   Aizawa, Yoshifusa ^c   Yamamoto, Tadashi ^c   Yamaguchi, Kenichi ^c   Takahashi, Toshihiro ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b School of Health Sciences   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Atrial natriuretic peptide; Betaxolol; Brain natriurefic peptide; Dilated cardiomyopathy; Heart failure; Rat model

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRAIN NATRIURETIC PEPTIDE; MESSENGER RNA; METHYLCELLULOSE; NATRIURETIC FACTOR;

ANIMAL MODEL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; HEART FAILURE; HEART PROTECTION; HEMODYNAMIC PARAMETERS; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BETAXOLOL; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; MALE; RATS; RATS, INBRED LEW; RNA, MESSENGER; SWINE;

EID: 12244258217     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Bohler S, Saubadu S, Scheldewaert R, et al. Betaxolol versus carvedilol in chronic heart failure (BETACAR Study). Arzneim-Forsch Drug Res 1999;49:311-7.
2. Muinck ED, Buchner-Moell D, Ven LLM, et al. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: A multicenter international randomized study of angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19:870-5.
3. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
4. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-Year follow-up of patients randomized in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet 1998;351:1180-1.
5. Australian and New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
6. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure: A systemic overview of randomized controlled trials. Eur Heart J 1997;8:560-5.
7. CIBIS Investigators and Committee. A randomized trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
8. Lechat P, Escolano S, Golmard JL et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997;96:2197-205.
9. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7.
10. Chinkers M, Garbers DL, Chang MS, et al. A membrane form of gyanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338:78-83.
11. Schulz S, Singh S, Bellet RA, et al. The primary stracture of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell 1989;58:1155-62.
12. Maack T, Suzuki M, Almedia FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675-8.
13. Appel RG. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992;262:F911-8.
14. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988;332:78-82.
15. Yoshimoto T, Naruse M, Naruse K, et al. Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology 1996;137:1102-7.
16. Gutkowska J, Nemer M, Sole MJ, Drouin J, Sirois P. Lung in an important source of atrial natriuretic factor in experimental cardiomyopathy. J Clin Invest 1989;83:1500-4.
17. Levin ER. Natriuretic peptide C-receptor: More than a clearance receptor. Am J Physiol 1993;264:E483-9.
18. Ohta Y, Watanabe K, Nakazawa M, et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovascul Pharmacol 2000;36:S19-23.
19. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-84.
20. Watanabe K, Ohta Y, Nakazawa M, et al. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000;130:1489-95.
21. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial. Lancet 1999;353:9-13.
22. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.